Zobrazeno 11 - 20
of 30
pro vyhledávání: '"Patrick K. Reville"'
Autor:
Elias Jabbour, Koichi Takahashi, Kapil N. Bhalla, Guillermo Garcia-Manero, Rashmi Malla, Naval Daver, Caitlin R. Rausch, Naveen Pemmaraju, Nitin Jain, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Patrick K. Reville, Michael Andreeff, Hagop M. Kantarjian, Maro Ohanian, Guillermo Montalban-Bravo, Gautam Borthakur, Kelly Marek, Nicholas J. Short, Koji Sasaki, Alessandra Ferrajoli, Ghayas C. Issa, Tapan M. Kadia, Mark Brandt, Courtney D. DiNardo
Publikováno v:
Blood. 138:367-367
Background The combination of venetoclax and 5-azacytidine (5-AZA) for older and unfit patients with newly diagnosed AML has led to significant improvements in remission rates and survival compared to 5-AZA alone. We previously reported encouraging r
Autor:
Patrick K. Reville, Zeev Estrov, Sherry Pierce, Srdan Verstovsek, Michael Andreeff, Alessandra Ferrajoli, Naveen Pemmaraju, Tapan M. Kadia, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Koji Sasaki, Maro Ohanian, Guillermo Garcia-Manero, Courtney D. DiNardo, Hagop M. Kantarjian, Graciela M. Nogueras González, Gautam Borthakur, Nitin Jain, Naval Daver
Publikováno v:
Blood. 136:44-45
Background Recent advances have led to higher response rates and improved survival in patients with newly diagnosed AML. However, early death, lack of response, and long term leukemia-free survival remain important challenges. Early mortality in AML
Autor:
Tapan M. Kadia, Maro Ohanian, Elias Jabbour, Farhad Ravandi, Courtney D. DiNardo, Michael Andreeff, Gautam Borthakur, Carlos E. Bueso-Ramos, Koji Sasaki, Hussein A. Abbas, Guillermo Garcia-Manero, Sherry Pierce, Marina Konopleva, Patrick K. Reville, Hagop M. Kantarjian, Nicholas J. Short, Naval Daver, Alexis Geppner
Publikováno v:
Blood. 136:25-26
Background Myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). While MS in the setting of concomitant medullary acute myeloid leukemia (AML) is relatively well described, much less is known about patients prese
Autor:
Elisabeth Paietta, Fangxin Hong, Brad S. Kahl, Kyung Mann Kim, Vaishalee P. Kenkre, Bartosz Grzywacz, Erik A. Ranheim, Patrick K. Reville, Lakeesha Carmichael, Eneida A. Mendonça, Amy K. Erbe, Wei Wang, Paul M. Sondel, Sandra J. Horning, Anna Hoefges, Yiqiang Song, Songwon Seo, Jeffrey S. Miller, Randy D. Gascoyne, Jacquelyn A. Hank
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Background The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-
Autor:
Patrick K. Reville, Sandesh Parajuli
Publikováno v:
Kidney Transplant Management ISBN: 9783030001315
Treatment option for patients with end stage renal disease (ESRD) include dialysis and kidney transplantation. Patients with ESRD are at an increased risk for cardiovascular events, mortality and hospitalization. Kidney transplantation is considered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e1ab8fa5e1a8e407cacdabcf4a00e6c
https://doi.org/10.1007/978-3-030-00132-2_2
https://doi.org/10.1007/978-3-030-00132-2_2
Autor:
Susan L. Cohn, Stephen D. Gillies, Ralph A. Reisfeld, Julie R. Park, Wei Wang, Alice L. Yu, M. Fevzi Ozkaynak, Patrick K. Reville, Jacquelyn A. Hank, Michael D. Hogarty, Wendy B. London, Andrew L. Gilman, Paul M. Sondel, Yiqiang Song, Arlene Naranjo, Lakeesha Carmichael, Mitchell B. Diccianni, Amy K. Erbe, John M. Maris, Katherine K. Matthay, Dustin Hess, KyungMann Kim, Eneida A. Mendonça
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 1
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re
Autor:
Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Paul M. Sondel
Publikováno v:
Frontiers in Immunology
Frontiers in immunology, vol 8, iss JUN
Frontiers in Immunology, Vol 8 (2017)
Frontiers in immunology, vol 8, iss JUN
Frontiers in Immunology, Vol 8 (2017)
Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported as
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 17(12)
There is limited information about the role of protocol kidney biopsies for de novo donor-specific antibodies (dnDSA) in kidney transplant recipients, especially in those with stable graft function. We initiated a routine posttransplant DSA monitorin
Autor:
Gonzalo V. Gonzalez-Stawinski, William M. Baldwin, Amy S. Nowacki, Lynne Klingman, Aiwen Zhang, David O. Taylor, Medhat Askar, Eileen Hsich, Nicholas G. Smedira, Randall C. Starling, Suzanne Bakdash, Jenna Daghstani, Nader Moazami, Patrick K. Reville
Publikováno v:
The Journal of Heart and Lung Transplantation. 32:1241-1248
Ventricular assist devices (VADs) are increasingly being used as a bridge to transplantation and have been implicated as a risk factor for allosensitization to human leukocyte antigens (HLA). We investigate the association between VAD and allosensiti
Autor:
Lakeesha Carmichael, Amy K. Erbe, Paul M. Sondel, Michael D. Hogarty, Julie R. Park, Wei Wang, Patrick K. Reville, Mitchell B. Diccianni, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, KyungMann Kim, Alice L. Yu
Publikováno v:
Cancer Research. 77:LB-048
Introduction: High-risk neuroblastoma (NBL) patients (pts) enrolled in a COG Phase 3 clinical trial (ANBL0032) were randomized to isotretinoin (RA) alone or Immunotherapy: dinutuximab (anti-GD2 mAb) + IL2 + GMCSF + RA (Yu et al., NEJM, 2010). Dinutux